Lacosamide Vivanta

Lacosamide, the active ingredient in Lacosamide Vivanta, is an anticonvulsant presented as an injectable solution for intravenous use. It treats partial‑onset seizures as adjunctive therapy in patients with epilepsy.

GNH USA supplies Lacosamide Vivanta as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals and clinics worldwide.

Lacosamide is an antiepileptic medication used in the management of seizure disorders.

Partial‑onset seizures: adjunctive therapy to reduce seizure frequency. Focal seizures: improves seizure control when added to existing regimens. Epilepsy: used in patients whose seizures are not adequately controlled by other agents.

Lacosamide may cause a range of adverse reactions.

Common Side Effects: - Dizziness - Nausea - Fatigue - Headache

Serious or Rare Side Effects: - Cardiac conduction abnormalities, such as PR‑interval prolongation - Severe skin reactions, including Stevens‑Johnson syndrome - Anaphylactic or severe hypersensitivity reactions

When using Lacosamide Vivanta, consider the following precautions.

Renal impairment: monitor renal function and adjust therapy as needed. Hepatic impairment: use with caution and observe liver enzymes. Cardiac conduction disorders: obtain baseline ECG and monitor for PR prolongation. Pregnancy: risk category unknown; weigh potential benefits against risks. Concomitant CNS depressants: may increase sedation; monitor patient closely. Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Lacosamide can interact with several medications; awareness of the interaction level is essential.

Major Interactions (Avoid): - Class I antiarrhythmics (e.g., quinidine): may exacerbate PR‑interval prolongation. - Strong CYP2C19 inhibitors (e.g., fluconazole): can increase lacosamide plasma concentrations. - Potent CYP3A4 inducers (e.g., rifampin): may reduce lacosamide effectiveness.

Moderate Interactions (Monitor Closely): - Other antiepileptics (e.g., carbamazepine, phenytoin): may alter lacosamide levels. - Central nervous system depressants (e.g., benzodiazepines, alcohol): may enhance sedation. - Drugs affecting cardiac conduction (e.g., beta‑blockers): require ECG monitoring.